In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|July 27, 2021
Sciex’s New ZenoTOF 7600 Mass Instrument System Offers Increased Analytical Precision
Author(s)BioPharm International Editors
Sciex’s recently launched accurate mass instrument, the ZenoTOF 7600 system, offers novel ion fragmentation and increased sensitivity for life science research and biotherapeutic development.
Advertisement
The ZenoTOF 7600 System, recently launched by Sciex in June 2021, is a mass liquid chromatography–mass spectrometry/mass spectrometry (LC–MS/MS) instrument that includes both Zeno trap and electron activated dissociation (EAD) fragmentation.
This new system enables scientists to better identify, characterize, and quantify molecules by generating data that has been previously unattainable, Sciex stated in a company press release. These capabilities are expected to help solve real analytical challenges and advance the development of new precision diagnostics and biotherapeutics.
Zeno trap pulsing delivers up to twenty times more sensitivity than traditional orthogonal time-of-flight technology, while EAD fragmentation can derive novel structural information from diverse compound types. With EAD fragmentation, the system can fully characterize individual lipids from a single spectrum, which can enable the discovery of novel lipid markers for cancer and inflammatory disease. EAD fragmentation also allows biopharma scientists to precisely detect and quantify protein glycosylation patterns and differentiate isomeric amino acids, which are both critical for ensuring that therapies are safe and do not produce adverse reactions.
Additionally, when compared to prior products, this new LC–MS/MS system can quantify up to 40% more proteins and analyze biobank samples five times faster, Sciex stated in the press release.
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5